These poor prognosis groups include patients with high tumor burden or high lactate dehydrogenase (LDH) levels, uveal melanoma, mucosal melanoma, brain metastases and anti-PD-1 refractory melanoma. This evidence concerns the gene PDCD1 and neoplasm.